AINEWS
Khosla Ventures leads the round for an agentic AI platform, Carebricks, that lets hospitals build and run their own clinical, operational, and administrative agents against live patient data.
Carebricks is the runtime. The $55M Series B Bunkerhill Health closed on July 16 prices a bet that hospitals, not vendors, will be the ones writing clinical agents.
Carebricks is Bunkerhill's agentic AI platform: a set of tools health systems use to build and deploy their own clinical, operational, and administrative agents, rather than license a fixed vendor product. Agents run against the hospital's own data and workflows, not a sandbox. Bunkerhill describes agentic AI as systems that act on clinician instructions inside hospital software, not chat interfaces that only answer questions.
Khosla Ventures, a prominent Silicon Valley firm, led the round, with Sequoia Capital, Felicis, Optum Ventures, and Y Combinator all doubling down. Five tier-one names on the same term sheet is the capital base that funds infrastructure plays rather than single-use apps.
The University of Texas Medical Branch (UTMB) is where Carebricks runs against live clinical data. Bunkerhill points to two outcomes from that deployment. A coronary calcium agent flagged findings that triggered an emergency triple bypass. Automated agents cut nephrology specialist wait times by more than 50% and flagged urgent incidental lung nodules. Both numbers are attributable to Bunkerhill and echoed by HIT Consultant; independent clinical evaluation has not been published. The company's framing is that most healthcare ML funding has gone to pilots that never touch a live patient chart, and UTMB is the receipt that Carebricks does.
The regulatory and billing rails explain why the bet is investable now. Bunkerhill holds two FDA 510(k) clearances: K260166 for Contrast CAC and K243229 for AVC. The company separately claims the first FDA clearance enabling automated aortic valve calcification quantification on non-cardiac CT. In April 2026, Bunkerhill secured a CMS billing code for both products. FDA clearance plus a CMS code is the difference between an agent that exists and an agent a hospital can bill for, and both pieces were in place before the Series B closed.
US healthcare spending reached $5.3T in 2024 per CMS, and labor shortages keep provider capacity tight. CEO Nishith Khandwala frames the gap as "Medicine has advanced faster than our healthcare system's ability to operationalise it." That is the company speaking for itself: the constraint is what staff have time to execute, not what clinicians know to do.
Bunkerhill's PR references "health systems already paying for it" in the plural but does not name one. A second system replicating UTMB at clinical scale with audited outcomes would confirm the substrate claim. Without one, the round is a clinical app dressed in platform clothing.
The $55M figure is cumulative across Bunkerhill's Seed, Series A, and Series B; the Series B tranche size is not disclosed.